Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy
Table 2
Mean (standard deviation) number of anti-VEGF therapy and PDT in the regimen of anti-VEGF monotherapy and the regimen of combination therapy for various subtypes of polypoidal choroidal vasculopathy during the 6-year period.